SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    International Agency for Research on Cancer. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. DeLellis R, Lloyd R, Heitz P, Eng C, eds. Lyon, France: IARC Press; 2004.
  • 2
    Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review). Oncol Rep. 2009;22:671-681.
  • 3
    Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714-720.
  • 4
    LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011;24(suppl 2):S1-S9.
  • 5
    Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
  • 6
    Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
  • 7
    Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
  • 8
    Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321:86-93.
  • 9
    Bentz BG, Miller BT, Holden JA, Rowe LR, Bentz JS. B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg. 2009;140:709-714.
  • 10
    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156:2165-2172.
  • 11
    Ali S, Cibas E, eds. The Bethesda System for Reporting Thyroid Cytopathology. New York, NY: Springer; 2010.
  • 12
    Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol. 2011;24(suppl 2):S34-S43.
  • 13
    Colanta A, Lin O, Tafe L, et al. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: Impact on diagnosis and prognosis. Acta Cytol. 2011;55:563-569.
  • 14
    Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res. 2004;10:2761-2765.
  • 15
    Kucukodaci Z, Akar E, Haholu A, Baloglu H. A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: In-house PCR assay for BRAF T1799A (V600E). Diagn Cytopathol. 2011;39:424-427.
  • 16
    Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143.
  • 17
    Troncone G, Cozzolino I, Fedele M, Malapelle U, Palombini L. Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol. 2010;38:172-176.
  • 18
    Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
  • 19
    Pelizzo MR, Boschin IM, Barollo S, et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med. 2011;49:325-329.
  • 20
    Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 2006;3:10.
  • 21
    Baloch ZW, Gupta PK, Yu GH, Sack MJ, LiVolsi VA. Follicular variant of papillary carcinoma. cytologic and histologic correlation. Am J Clin Pathol. 1999;111:216-222.
  • 22
    Bernstein JI, Virk R, Hui P, et al. Tall cell variant of papillary thyroid microcarcinoma: clinicopathological features with BRAFV600E mutational analysis. Thyroid. 2013; doi:10.1089/thy.2013.0154.
  • 23
    Lang AH, Drexel H, Geller-Rhomberg S, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn. 2011;13:23-28.
  • 24
    Wellcome Trust Sanger Institute. COSMIC (Catalogue of Somatic Mutations in Cancer Web site). Mutation overview BRAF p.L597Q (substitution–missense). http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=1125. Accessed June 7, 2013.
  • 25
    Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia. 2005;19:310-312.
  • 26
    Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-1890.